Spero Therapeutics, Inc. (SPRO)
About Spero Therapeutics, Inc.
Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. It is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $12.6M
- Net income
- $8.6M
- Total assets
- $68.9M
- Market cap
- $163.3M
- Operating margin
- 9.5%
- Net margin
- 12.8%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $66.8M
- Operating expenses
- $60.5M
- Operating income
- $6.3M
- Income tax
- $261.0K
- Net income
- $8.6M
- EPS (basic)
- $0.15
- EPS (diluted)
- $0.15
Balance sheet
- Total assets
- $68.9M
- Current assets
- $67.3M
- Total liabilities
- $9.9M
- Current liabilities
- $8.9M
- Shareholders’ equity
- $59.0M
Cash flow
- Operating cash flow
- -$12.6M
- Net cash flow
- -$12.6M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year · hover for prices
52-week range
- Market cap
- $163.3M
- P/E ratio
- 7.9
- EPS (diluted)
- $0.15
- Shares outstanding
- 137.2M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Nov 2, 2017
Spero Therapeutics, Inc. (SPRO) Stock Price
- Profitable — net income of $8.6M in FY2025.
- Revenue grew 266% from FY2021 to FY2025.
- Trading 61% below its 52-week high.
- Valued at a price-to-earnings (P/E) ratio of 7.9.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Spero Therapeutics, Inc..
Write a review
News about Spero Therapeutics, Inc.
News & sentiment via Polygon.io
Spero Therapeutics, Inc.: frequently asked questions
Is Spero Therapeutics, Inc. an American company?
Spero Therapeutics, Inc. is a US-based company headquartered in Cambridge, Massachusetts, listed in the americancompanies.com directory of American companies. Its American-origin credentials have not yet been independently verified.
Where is Spero Therapeutics, Inc. headquartered?
Spero Therapeutics, Inc. is headquartered in Cambridge, Massachusetts, United States.
Is Spero Therapeutics, Inc. publicly traded?
Yes — Spero Therapeutics, Inc. is a publicly traded company. Its stock trades under the ticker symbol SPRO on the NASDAQ.
What does Spero Therapeutics, Inc. do?
Spero Therapeutics, Inc. is an American Pharmaceuticals company in the Health & Beauty sector.
